304P ESR1 mutations and outcomes in BRCA1/2 or PALB2 germline mutation carriers receiving first line aromatase inhibitor + palbociclib (AI+P) for metastatic breast cancer (MBC) in the PADA-1 trial

Jean‐Sébastien Frenel, Florence Dalenc, Barbara Pistilli, T. De La Motte Rouge, Christelle Lévy, M-A Mouret-Reynier, A-C. Hardy-Bessard, Nathalie Bonichon-Lamichhane, Charlotte Greilsamer, Valérie Delecroix, Suzanne Nguyen, Frédérique Berger, Sibille Everhard, Jérôme Lemonnier, Delphine Loirat, Céline Callens, Anne Pradines, Thomas Bachelot, Suzette Delaloge, François‐Clément Bidard